![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SRBD1 |
Gene summary for SRBD1 |
![]() |
Gene information | Species | Human | Gene symbol | SRBD1 | Gene ID | 55133 |
Gene name | S1 RNA binding domain 1 | |
Gene Alias | SRBD1 | |
Cytomap | 2p21 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q8N5C6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
55133 | SRBD1 | NAFLD1 | Human | Liver | NAFLD | 1.65e-09 | 7.58e-01 | -0.04 |
55133 | SRBD1 | HCC1_Meng | Human | Liver | HCC | 2.95e-22 | -4.07e-02 | 0.0246 |
55133 | SRBD1 | HCC2_Meng | Human | Liver | HCC | 4.37e-04 | -3.03e-02 | 0.0107 |
55133 | SRBD1 | HCC1 | Human | Liver | HCC | 3.76e-02 | 4.29e+00 | 0.5336 |
55133 | SRBD1 | HTA12-25-1 | Human | Pancreas | PDAC | 1.85e-05 | 6.44e-01 | 0.313 |
55133 | SRBD1 | HTA12-26-1 | Human | Pancreas | PDAC | 1.24e-12 | 6.97e-01 | 0.3728 |
55133 | SRBD1 | HTA12-29-1 | Human | Pancreas | PDAC | 2.09e-22 | 5.78e-01 | 0.3722 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SRBD1 | SNV | Missense_Mutation | novel | c.1472N>G | p.Asp491Gly | p.D491G | Q8N5C6 | protein_coding | deleterious(0) | possibly_damaging(0.859) | TCGA-3C-AAAU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | zoladex | SD |
SRBD1 | SNV | Missense_Mutation | rs376984926 | c.1610G>A | p.Arg537His | p.R537H | Q8N5C6 | protein_coding | deleterious(0.02) | possibly_damaging(0.899) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
SRBD1 | SNV | Missense_Mutation | c.2043G>A | p.Met681Ile | p.M681I | Q8N5C6 | protein_coding | deleterious(0.02) | benign(0.23) | TCGA-A2-A0EO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
SRBD1 | SNV | Missense_Mutation | rs779181595 | c.2617N>A | p.Glu873Lys | p.E873K | Q8N5C6 | protein_coding | tolerated(0.64) | benign(0) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SRBD1 | SNV | Missense_Mutation | c.1381N>C | p.Glu461Gln | p.E461Q | Q8N5C6 | protein_coding | tolerated(0.13) | benign(0.074) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
SRBD1 | SNV | Missense_Mutation | c.532N>G | p.Gln178Glu | p.Q178E | Q8N5C6 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
SRBD1 | SNV | Missense_Mutation | c.402N>C | p.Lys134Asn | p.K134N | Q8N5C6 | protein_coding | tolerated_low_confidence(0.09) | probably_damaging(0.994) | TCGA-AR-A1AO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
SRBD1 | SNV | Missense_Mutation | novel | c.2236N>A | p.Glu746Lys | p.E746K | Q8N5C6 | protein_coding | deleterious(0.01) | possibly_damaging(0.894) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SRBD1 | SNV | Missense_Mutation | c.1805N>C | p.Arg602Thr | p.R602T | Q8N5C6 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-C8-A1HK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SRBD1 | SNV | Missense_Mutation | rs769234107 | c.1596N>A | p.Ser532Arg | p.S532R | Q8N5C6 | protein_coding | tolerated(0.06) | benign(0.08) | TCGA-C8-A1HK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |